Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy raises £10mln at a premium

The fundraising is led by Paris-based DNCA Investments which is investing £4.8mln; small change for a company with more than £23bn assets under management
harley street
The new shares will represent 12.8% of the enlarged share capital of the company

Advanced Oncotherapy PLC (LON:AVO) is raising £10.0mln as it presses ahead with the building of its next-generation LIGHT proton therapy system on Harley Street.

Investors taking part in the fundraising, including Paris-based DNCA Investments, are paying 40p a share – an 11% premium to Thursday’s closing price.

READ: AVO improves performance of LIGHT system

As well as funding the continued development of the first LIGHT system, the money will also pay for software development and costs relating to the new testing and assembly site being set up at a science park in Cheshire.

In its last stock exchange announcement in October, AVO announced it had doubled the power of the proton beam in the LIGHT system.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Article
September 28 2018

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use